Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)
Antolín Novoa, Silvia, Escrivá-de-Romaní, Santiago, Tolosa Ortega, Pablo, Oliva Fernández, Lucía, López López, Rafael, López González, Ana, de la Morena Barrio, Pilar, Echavarria Díaz-Guardamino, Isabel, Alés Martinez, José Enrique, Garate, Zita, González-Cortijo, Lucia
Published in Cancer treatment and research communications (2023)
Published in Cancer treatment and research communications (2023)
Get full text
Journal Article